JYS-1

JYS-1 is a biological drug candidate developed by Hangzhou Jiuyuan Genetic Biopharmaceutical that targets the glucagon-like peptide-1 receptor (GLP-1R). It is being developed for the treatment of obesity and overweight. As a GLP-1 receptor agonist, it mimics the effects of the endogenous incretin hormone GLP-1 to regulate appetite, enhance satiety, and slow gastric emptying, thereby promoting weight loss. According to company pipeline information, JYS-1 has reached the New Drug Application (NDA) stage in China, with a submission reported in early 2025. While some pipeline records categorize its modality as a polyclonal antibody, it is part of a broader portfolio of GLP-1 targeted therapies for metabolic disorders.